GN-CORPORATION
Caucasian, Hispanic and Afro-American population, when Covid-19 infected, are prone to abnormal blood clotting, that may lead to stroke. Pregnant women and people with comorbidities are also at high risk. Higher mortality has been reported in patients, whose fasting plasma glucose is very high at the time of hospital admission with SARS-COV-2. During this unprecedented pandemic, a prophylaxis to Covid-19 in diabetic population , and strategies for Prevention of Covid-19 associated coagulopathy by consumption of Beta glucan food supplement produced by Black yeast Aureobasidium Pullulans AFO-202 strain has been published in Journal of Diabetes and Metabolic Disorders (https://doi.org/10.1007/s40200-020-00664-4 ) and Thrombosis Journal (https://doi.org/10.1186/s12959-020-00239-6 ) respectively, recommending clinical studies for its validation in Covid-19 patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201025005031/en/
COVID-19 virus damages blood vessels, causing clot or thrombus formation resulting in stroke and disruption of the body’s blood clotting system, leading to organ damage and death. Metabolic and immune dysregulation leads to higher mortality in diabetes patients. The AFO-202 derived Nichi-Glucan has potentials to alleviate the cytokine storm, minimize coagulation disruption, and prevent complications of Covid-19 by balancing blood glucose & cholesterol, according to the authors, who have earlier published its immune enhancement and modulation capabilities to help tackle Covid-19 (https://doi.org/10.3389/fimmu.2020.01548 ). Pilot studies in Diabetic and Dyslipidemic individuals from south Asian population also have been reported (https://doi.org/10.1155/2012/895370 ).
Unique advantages: Research of Prof. Noboru Fujii on poly-thermo tolerant fungi lead to the successful culture of Aureobasidium Pullulans and Mr. Takashi Onaka (President, Sophy Inc) accomplished its industrial scale GMP production in Kochi, Japan, which was approved by Japanese health ministry as a food additive and in the market since 1996. Among several ß-Glucans produced by extraction and purification methods from sources like yeast-cell wall, Shiitake mushroom, Oats, Algae etc, Nichi Glucan is unique, being secreted as an exo-polysaccharide by AFO-202, possessing a distinct structure, water solubility, high purity, functionality and molecular weight of 30,000. Safety has been confirmed by genotoxicity, repeated and long-term administration tests. Recently, a new strain, N-163 secreted product, having advantageous characteristics to contribute to human health is undergoing studies. Nichi Glucan is available in Japan (www.nichiglucan.com ) and in India (https://www.amazon.in/dp/B08DFDX2HQ ), exported worldwide by GN Corporation.
Disclaimer: Nichi-Glucan is a food supplement, free from 25 most common allergens. It’s not a drug or curative/therapeutic agent.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201025005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 01:00:00 CET | Press release
Stakeholder base expands with participation from an individual-investor-oriented fund, alongside corporate and individual investors, bringing Total Funding to USD 38M Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helic
Andersen Consulting udvider sin tilstedeværelse gennem samarbejde med Hilal Technology4.12.2025 23:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Hilal Technology for at styrke sine kompetencer inden for digital infrastruktur, cybersikkerhed og AI. Med tilstedeværelse i Bahrain, Saudi-Arabien, De Forenede Arabiske Emirater, Oman og Indien leverer Hilal Technology et komplet spektrum af digital infrastruktur og managed services inden for cloudcomputing, cybersikkerhed, enterprise ai og systemintegration. Deres ydelser omfatter cloudtjenester, sikkerheds- og netværksdrift, implementering af ERP og applikationer samt udvikling af generative ai-kapaciteter. Med et team på mere end 250 fagfolk servicerer firmaet en bred vifte af brancher, herunder den finansielle sektor, olie og gas, logistik og den offentlige sektor. "Transformation er mere end systemer; det handler om parathed, tillid og løbende samarbejde," udtaler Roshan George, direktør for Hilal Technology. "Vi er begejstrede for at samarbejde med Andersen Consulting og levere skalerbare løsninger, der matcher tempoet i den dig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom